表紙
市場調查報告書

過敏免疫治療的全球市場:成長,趨勢,及預測

Allergy Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 911972
出版日期 內容資訊 英文 101 Pages
商品交期: 2-3個工作天內
價格
Back to Top
過敏免疫治療的全球市場:成長,趨勢,及預測 Allergy Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年11月01日內容資訊: 英文 101 Pages
簡介

本報告提供全球過敏免疫治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,免疫治療類型·過敏類型·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析

第5章 市場區隔

  • 各免疫治療類型
    • 皮下免疫療法(SCIT)
    • 舌下免疫療法(SLIT)
    • 其他
  • 各過敏類型
    • 過敏性鼻炎
    • 氣喘
    • 食物過敏
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Aimmune Therapeutics
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Biomay AG
    • Circassia
    • HAL Allergy Group
    • Hollister Allergy
    • Leti Pharma
    • Merck KGaA (Allergopharma)
    • Stallergenes Greer

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 66803

Market Overview

The major factors for the growth of the allergy immunotherapy market include the increasing burden of various types of allergies and the launch of new sublingual immunotherapies in emerging economies.

The rising cases of allergies are expected to increase the demand for allergy immunotherapy, leading to the high growth of the market over the forecast period. According to the International Study of Asthma and Allergies in Childhood (ISAAC), about 22.1% of young children aged between 13 and 14 years are affected by hay fever, which was globally published in World Allergy Week 2016 fact sheet. As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost in excess of USD 18 billion, and more than 50 million Americans suffer from allergies each year. There is an increase in the number of people suffering from food allergies among both children and adults, globally. Hence, the increasing burden of allergic diseases is expected to aid the demand for novel immunotherapies.

Scope of the Report

As per the scope of this report, allergy immunotherapies are a preventive treatment for allergic reactions to substances. It involves gradually increasing doses of the substance, or allergen, to which the person is allergic. The market is segmented by type of immunotherapy, allergy type and geography.

Key Market Trends

Subcutaneous Immunotherapy (SCIT) is the Segment by Immunotherapy Type expected to Hold Largest Market Share

The subcutaneous immunotherapy (SCIT), is the most commonly used and most effective form of allergy immunotherapy and it is the only treatment available that actually changes the immune system, making it possible to prevent the development of new allergies and asthma. The rising approval of immunotherapy is the major factor driving the growth of the market. For instance, recently, in 2018, one of the major market players, Stallergenes Greer received approval from the United States Food and Drug Administration (FDA) for the extension of the indication for Oralair, an allergy immunotherapy sublingual tablet, to treat patients ages 5 to 9 with grass pollen-induced allergic rhinitis. Furthermore, governments are taking initiatives to increase the awareness about allergies among the population, for instance recently, in January 2018, the Ministry and the Japanese Society of Allergology opened a dedicated website about allergies. Thus, owing to the rising burden of allergies and awareness among the population the market is expected to witness high growth.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest allergy immunotherapy market across the world. High prevalence of allergies and stringent regulatory guidelines that mandate allergic testing in all cases of intensive and emergency care are some of the factors contributing to the growth of the US allergy immunotherapy market. It is estimated that one among every six Americans (around 50 million) suffers from some form of allergy, and around 25 million Americans suffer from respiratory allergies. Among the Americans suffering from respiratory allergies, approximately 10 million suffer from allergic asthma. In the United States, ragweed allergy is the primary reason for hay fever (pollen allergies), and ragweed pollen production is expected to increase by about 65% - 100% by 2085. This is gradually contributing to the growth of the market studied. Furthermore, the availability of better healthcare infrastructure is expected to drive the growth of the market studied.

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. Some of the market players are Aimmune Therapeutics, Hollister Allergy, Leti Pharma, Merck KGaA (Allergopharma), Stallergenes Greer, Allergy Therapeutics, ALK-Abello A/S, HAL Allergy Group, Biomay AG, and Circassia

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTs

1. INTRODUCTION

  • 1.1. Study Deliverables
  • 1.2. Study Assumptions
  • 1.3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. Market Overview
  • 4.2. Market Drivers
    • 4.2.1. Increasing Burden of Various Types of Allergies
    • 4.2.2. Launch of New Sublingual Immunotherapies in Emerging Economies
  • 4.3. Market Restraints
    • 4.3.1. Lack of Awareness about Allergy and Treatments
  • 4.4. Porter's Five Force Analysis
    • 4.4.1. Threat of New Entrants
    • 4.4.2. Bargaining Power of Buyers/Consumers
    • 4.4.3. Bargaining Power of Suppliers
    • 4.4.4. Threat of Substitute Products
    • 4.4.5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1. By Type of Immunotherapy
    • 5.1.1. Subcutaneous Immunotherapy (SCIT)
    • 5.1.2. Sublingual Immunotherapy (SLIT)
  • 5.2. By Allergy Type
    • 5.2.1. Allergic Rhinitis
    • 5.2.2. Asthma
    • 5.2.3. Food Allergy
    • 5.2.4. Others
  • 5.3. Geography
    • 5.3.1. North America
      • 5.3.1.1. US
      • 5.3.1.2. Canada
      • 5.3.1.3. Mexico
    • 5.3.2. Europe
      • 5.3.2.1. Germany
      • 5.3.2.2. UK
      • 5.3.2.3. France
      • 5.3.2.4. Italy
      • 5.3.2.5. Spain
      • 5.3.2.6. Rest of Europe
    • 5.3.3. Asia Pacific
      • 5.3.3.1. China
      • 5.3.3.2. Japan
      • 5.3.3.3. India
      • 5.3.3.4. Australia
      • 5.3.3.5. South Korea
      • 5.3.3.6. Rest of Asia-Pacific
    • 5.3.4. Middle East and Africa
      • 5.3.4.1. GCC
      • 5.3.4.2. South Africa
      • 5.3.4.3. Rest of Middle East and Africa
    • 5.3.5. South America
      • 5.3.5.1. Brazil
      • 5.3.5.2. Argentina
      • 5.3.5.3. Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1. Company Profiles
    • 6.1.1. Torii Pharmaceutical Co., Ltd.
    • 6.1.2. ALK-Abello A/S
    • 6.1.3. Allergy Therapeutics
    • 6.1.4. Biomay AG
    • 6.1.5. Allovate, LLC
    • 6.1.6. HAL Allergy Group
    • 6.1.7. Hollister Allergy
    • 6.1.8. Leti Pharma
    • 6.1.9. Merck KGaA (Allergopharma)
    • 6.1.10. Stallergenes Greer

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top